I-Mab reports Q3 EPS (25c) vs. (39c) last year

Reports no revenue in Q3 vs. $315K last year. The company expects its existing cash and cash related balances to be sufficient to fund its current operating plan into 2027. “I-Mab (IMAB) is making excellent progress in advancing the development of our pipeline projects, supported by our strong cash balance, streamlined operating model, and a focused in-licensing strategy,” said Sean Fu, CEO. “In addition, Phase 1 data presented this year for uliledlimab, givastomig, and ragistomig at four international medical conferences highlight the strength of our early data sets for each program. These results have provided us with a strong foundation for advancing each molecule into expanded clinical trials, including Phase 2 studies, in the next year.”